Log In
Print
BCIQ
Print
Print this Print this
 

Tenofovir 1% vaginal gel

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
Description1% vaginal gel formulation of tenofovir, a nucleotide analog prodrug reverse transcriptase inhibitor
Molecular Target HIV reverse transcriptase
Mechanism of ActionHIV reverse transcriptase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationHIV / AIDS
Indication DetailsPrevent HIV infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today